Table 3.
The results of expression study of lncRNAs in peripheral blood of patients with PD compared with healthy controls.
| lncRNAs | Total patients vs. Controls (50 vs. 58) | Male patients vs. Male Controls (37 vs. 38) | Female patients vs. Female Controls (13 vs. 20) | Female patients vs. Male patients 13 vs. 37) | |
|---|---|---|---|---|---|
| HULC | Expression ratio (Lower Limit-Upper Limit) | 0.19 (0.130-0.279) | 0.513 (0.339-0.775) | 0.071 (0.037-0.134) | 0.962 (0.318-1) |
| Adjusted P Value | <0.0001* | 0.3746 | 0.0004 | 0.757 | |
| PVT1 | Expression ratio (Lower Limit-Upper Limit) | 0.55 (0.435-0.696) | 0.619 (0.479-0.799) | 0.49 (0.33-0.727) | 0.962 (0.673-1.375) |
| Adjusted P Value | 0.0124* | 0.2430 | 0.2770 | 0.999 | |
| DSCAM-AS1 | Expression ratio (Lower Limit-Upper Limit) | 5.672 (3.208-10.029) | 9.526 (5.124-17.71) | 3.375 (1.296-8.784) | 0.116 (0.048-0.276) |
| Adjusted P Value | 0.0029* | 0.0024* | 0.5826 | 0.0683 | |
| SPRY4-IT | Expression ratio (Lower Limit-Upper Limit) | 2.64 (1.735-4.019) | 3.434 (2.174-5.432) | 2.03 (1-4.106) | 0.913 (0.482-1.728) |
| Adjusted P Value | <0.0227 | <0.0397* | <0.7471 | 0.9999 | |
| LINC-ROR | Expression ratio (Lower Limit-Upper Limit) | 10.36 (6.236-17.21) | 4.575 (2.634-7.948) | 23.47 (10.014-55.024) | 0.854 (0.395-1.848) |
| Adjusted P Value | <0.0001* | 0.0345* | 0.0019* | 0.9970 | |
| MEG3 | Expression ratio (Lower Limit-Upper Limit) | 13.94 (7.86-24.706) | 8.603 (4.615-16.037) | 22.58 (8.639-59.014) | 1.392 (0.583-3.321) |
| P-value | <0.0001 | <0.0044* | <0.0085* | 0.9811 | |
The expression ratio of each gene (mean, lower limit and upper limit) is shown as the ratio of expression of the first group compared to the second group in each column.
* shows significance.